Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

1.

Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.

Boutin B, Tajeddine N, Vandersmissen P, Zanou N, Van Schoor M, Mondin L, Courtoy PJ, Tombal B, Gailly P.

Prostate. 2013 Jul;73(10):1090-102. doi: 10.1002/pros.22658. Epub 2013 Mar 26.

PMID:
23532738
[PubMed - indexed for MEDLINE]
2.

Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.

Kaini RR, Sillerud LO, Zhaorigetu S, Hu CA.

Prostate. 2012 Sep 15;72(13):1412-22. doi: 10.1002/pros.22489. Epub 2012 Jan 31.

PMID:
22294520
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

Thomas C, Wafa LA, Lamoureux F, Cheng H, Fazli L, Gleave ME, Rennie PS.

Prostate. 2012 Jun 1;72(8):875-85. doi: 10.1002/pros.21490. Epub 2011 Oct 5.

PMID:
22072572
[PubMed - indexed for MEDLINE]
4.

Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?

Bennett HL, Stockley J, Fleming JT, Mandal R, O'Prey J, Ryan KM, Robson CN, Leung HY.

BJU Int. 2013 Apr;111(4):672-82. doi: 10.1111/j.1464-410X.2012.11409.x. Epub 2012 Aug 16.

PMID:
22897391
[PubMed - indexed for MEDLINE]
5.

Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.

Quéro L, Giocanti N, Hennequin C, Favaudon V.

Prostate. 2010 Mar 1;70(4):401-11. doi: 10.1002/pros.21074.

PMID:
19902473
[PubMed - indexed for MEDLINE]
6.

Prostate cancer: Could an antimalarial drug delay the onset of CRPC?

Clyne M.

Nat Rev Urol. 2013 Jun;10(6):307. doi: 10.1038/nrurol.2013.83. Epub 2013 Apr 16. No abstract available.

PMID:
23588402
[PubMed - indexed for MEDLINE]
7.

Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.

Danquah M, Duke CB 3rd, Patil R, Miller DD, Mahato RI.

Pharm Res. 2012 Aug;29(8):2079-91. doi: 10.1007/s11095-012-0737-1. Epub 2012 Mar 27.

PMID:
22451249
[PubMed - indexed for MEDLINE]
8.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.

Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

PMID:
18324645
[PubMed - indexed for MEDLINE]
9.

Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.

Mitterberger M, Neuwirt H, Cavarretta IT, Hobisch A, Culig Z.

Prostate. 2007 Aug 1;67(11):1194-201.

PMID:
17520660
[PubMed - indexed for MEDLINE]
10.

Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.

Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.

Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.

PMID:
18454446
[PubMed - indexed for MEDLINE]
11.

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.

Br J Cancer. 1999 Sep;81(2):242-51.

PMID:
10496349
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.

McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.

J Cell Biochem. 2010 Aug 1;110(5):1187-94. doi: 10.1002/jcb.22633.

PMID:
20589722
[PubMed - indexed for MEDLINE]
13.

Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.

Floyd MS Jr, Teahan SJ, Fitzpatrick JM, Watson RW.

Prostate Cancer Prostatic Dis. 2009;12(1):25-33. doi: 10.1038/pcan.2008.23. Epub 2008 May 13. Erratum in: Prostate Cancer Prostatic Dis. 2011 Dec;14(4):367. Floyd, M St John Jr [corrected to Floyd, M S Jr].

PMID:
18475288
[PubMed - indexed for MEDLINE]
14.

Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.

Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.

PMID:
19152342
[PubMed - indexed for MEDLINE]
15.

Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.

Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.

Prostate. 2010 Feb 1;70(2):179-89. doi: 10.1002/pros.21051.

PMID:
19790234
[PubMed - indexed for MEDLINE]
16.

5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.

Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V, Festuccia C.

Prostate. 2010 Aug;70(11):1166-78. doi: 10.1002/pros.21151.

PMID:
20333699
[PubMed - indexed for MEDLINE]
17.

In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.

Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, Vicentini C, Bologna M.

Prostate. 2007 Sep 1;67(12):1255-64.

PMID:
17596848
[PubMed - indexed for MEDLINE]
18.

Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.

Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, Ip C.

Anticancer Res. 2010 Oct;30(10):3895-901.

PMID:
21036700
[PubMed - indexed for MEDLINE]
19.

Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.

Prostate. 2010 Apr 1;70(5):457-66. doi: 10.1002/pros.21079.

PMID:
19902465
[PubMed - indexed for MEDLINE]
20.

Micellar delivery of bicalutamide and embelin for treating prostate cancer.

Danquah M, Li F, Duke CB 3rd, Miller DD, Mahato RI.

Pharm Res. 2009 Sep;26(9):2081-92. doi: 10.1007/s11095-009-9903-5. Epub 2009 May 5.

PMID:
19415464
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk